Wagner José Tenório dos Santos

Dr. Wagner José Tenório dos Santos

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
WSWagner José Tenório dos Santos
Wagner José Tenório dos Santos
DTDiego H. C. Tavares
Diego H. C. Tavares
ANArtur L. Castro Neto
Artur L. Castro Neto
MNMarília B. Nascimento
Marília B. Nascimento
RDRafael Dhalia
Rafael Dhalia
ONOsvaldo P. de Melo Neto
Osvaldo P. de Melo Neto
Visceral leishmaniasis (VL) is a major neglected disease, potentially fatal, whose control is still impaired by inefficient and/or expensive treatment and diagnostic methods. The most promising approach for VL diagnosis uses serological assays with recombinant proteins, since they are more efficient and easier to perform. Tests developed for the human form of the disease, however, have not been shown to be efficient for its diagnosis in the canine host, the major reservoir for the American VL. Here, we describe a systematic approach aimed at the production of a new chimeric protein potentially able to be used for both human and canine VL diagnosis and based both on in silico gene design and experimental data. Starting from the previous identification of Leishmania infantum recombinant antigens efficient for the diagnosis of either human or canine VL, three of the best performing antigens were selected (Lci2, Lci3 and Lci12). After a preliminary evaluation validating the chimeric approach, DNA fragments encoding predicted antigenic regions from each protein, enriched with repeats, were joined in various combinations to generate a total of seventeen chimeric genes optimized for prokaryotic expression. These were assessed for optimal expression and purification yield, with four chimeric proteins being efficiently produced. Their diagnostic potential was then evaluated through ELISA assays with sera from VL afflicted humans and dogs. After two rounds of gene design, the results showed high levels of sensitivity for the best chimeric protein, named Q5, in humans (82%) and dogs (100%) with 100% specificity in comparison with healthy controls. A single non-specific reaction was seen with serum from individuals with tegumentary leishmaniasis. The newly described chimeric protein is potentially useful for the detection of both humans and dogs afflicted with VL, with its use in rapid tests necessary for validation as a new diagnostic tool. Visceral leishmaniasis (VL) is a major neglected disease, potentially fatal, caused mainly by Leishmania infantum and L. donovani. Its control is still impaired by inefficient and/or expensive treatment and diagnostic methods. VL diagnosis is mostly dependent on serological assays made with bacterially expressed Leishmania proteins. Tests developed for the human form of the disease, however, are not efficient for its diagnosis in the canine host. Dogs are the major reservoir for the American VL and their infection also needs to be monitored, requiring a distinct diagnostic test. Here, we describe a new chimeric protein potentially able to be used for both human and canine VL diagnosis. Based on a systematic approach using three Leishmania proteins known to be efficient for the diagnosis of either human or canine VL, fragments of each were joined in various combinations. The diagnostic potential of different chimeric proteins was then evaluated with human and canine sera from VL afflicted individuals. The best protein showed high levels of sensitivity in humans and dogs with no relevant false positive results with healthy controls or humans with tegumentary leishmaniasis. It is then potentially useful for the detection of both humans and dogs afflicted with VL in novel diagnostic tests.

7 October 2023 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
LPLarissa Ferreira de Araújo Paz
Larissa Ferreira de Araújo Paz
ASAdalúcia da Silva
Adalúcia da Silva
HSHemilly Rayanne Silva
Hemilly Rayanne Silva
MPMilena Paiva-Cavalcanti
Milena Paiva-Cavalcanti
VLValéria Marçal Felix de Lima
Valéria Marçal Felix de Lima
WSWagner José Tenório dos Santos
Wagner José Tenório dos Santos
Dogs are considered the major domestic reservoir for human visceral leishmaniasis, a serious disease caused by the Leishmania infantum parasite. Diagnosis of canine visceral leishmaniasis (CVL) is critical for disease control, with several methods currently available. Among the serological tests, the DPP rapid test and the EIE-LVC, more commonly used in Brazil, are associated with variable sensitivity and specificity. Research with novel recombinant proteins such as the ELISA with the recombinant chimeric protein Q5 may therefore improve the CVL diagnosis. This study aimed to evaluate the true diagnostic potential of Q5 in an ELISA assay using a large number of CVL-suspected sera (406) with a previous positive diagnosis based on the rapid DPP test. Sera from the DPP-positive dogs, also assessed with the EIE-LVC test, were compared with sera from healthy dogs (n = 46) and used for ELISA tests using the recombinant Q5. The resulting data as well as the correlation with the clinical signs and the environmental characteristics of the animals were analyzed using Medal and GraphPad Prism 8.0. Overall, similar levels of lower sensitivity (67–68%) were seen for both the commercial EIE-LVC test and the Q5 ELISA when all assessed sera were considered, but a much greater sensitivity (92%) was seen for those samples from symptomatic dogs only. In contrast, many negative results were observed for the DPP-positive sera from asymptomatic dogs or those with no clinical information available. A selection of those sera were tested yet again in new ELISA assays using a second batch of the recombinant Q5, purified under milder denaturing conditions, as well as using another recombinant protein (Lci13). The results reveal a higher-than-expected incidence of likely false-positive results for DPP, reinforcing the need for other recombinant proteins, such as the chimeric Q5, to be investigated as possible alternatives to the currently used CVL diagnostic methods.

17 April 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
LSLucas Portela Silva
Lucas Portela Silva
ESElis Dionisio Silva
Elis Dionisio Silva
APAllana Maria de Souza Pereira
Allana Maria de Souza Pereira
WSWagner José Tenório dos Santos
Wagner José Tenório dos Santos
ASAnderson Henrique da Silva
Anderson Henrique da Silva
VPValéria Rêgo Alves Pereira
Valéria Rêgo Alves Pereira
Background: Visceral leishmaniasis (VL) is a neglected disease caused by species of the Leishmania donovani complex and transmitted mainly by the bite of infected sandflies. A less frequent form of transmission is the transfusion route, important in countries lacking screening procedures for VL in blood banks. Methods: To identify asymptomatic infection by Leishmania sp, our goal here was to evaluate and compare the performance of three different serological techniques: Flow Cytometry (FC); Direct Agglutination Test (DAT); and Immunoenzymatic Test (ELISA). Thirty-one asymptomatic carriers of L. infantum were selected, from a single blood bank located in Recife, northeastern Brazil. Results : Foi avaliada a frequência de amostras positivas assintomáticas nos testes, no ELISA baseado no antígeno solúvel de Leishmania (25,8%), FC (22,8%), DAT (9,7%) e ELISA baseado em uma única proteína recombinante (12,9%). A sensibilidade dos testes também foi avaliada, o FC (22,58%) e o ELISA com o antígeno solúvel (22,58%) apresentaram os maiores valores de sensibilidade que o DAT (6,45%) e o ELISA recombinante (12,9%). Apenas a CF apresentou baixa especificidade (22,22%), em contraste com as demais técnicas (100% de especificidade). Conclusion: Given the results presented, we highlight the low effectiveness of serological techniques for the identification of asymptomatic individuals, thus emphasizing the need to develop more accurate methods for this purpose.

21 March 2023 in Research Square
Verified
Preprint
Open access
PDF file
LPLarissa Ferreira de Araújo Paz
Larissa Ferreira de Araújo Paz
ASAdalúcia da Silva
Adalúcia da Silva
HSHemilly Rayanne Ferreira da Silva
Hemilly Rayanne Ferreira da Silva
MPMilena Paiva-Cavalcanti
Milena Paiva-Cavalcanti
VLValéria Marçal Felix de Lima
Valéria Marçal Felix de Lima
WSWagner José Tenório dos Santos
Wagner José Tenório dos Santos
Background Dogs are considered the major domestic reservoir for the human visceral leishmaniasis, a serious disease caused by the Leishmania infantum parasite. Diagnosis of the canine visceral leishmaniasis (CVL) is critical for disease control, with several methods currently available. Among the serological tests, the DPP rapid test and the EIE-LVC, more commonly used in Brazil, are associated with variable sensitivity and specificity. Research with novel recombinant proteins may therefore improve on the CVL diagnosis, such as the ELISA with the recombinant chimeric protein Q5. This study aimed to compare the Q5 in ELISA with the EIE-LVC (Leishmania major) using a large number ofCVL suspected sera (406) with a previous diagnosis based on the rapid DPP test. Methods Serum samples from dogs CVL positive in the rapid DPP test (n=406) and negative samples from healthy dogs (n=46) were used for ELISA tests using recombinant proteins Q5 and Lci13. The data obtained in the ELISA as well as the correlation with the clinical signs and the Socio-environmental characteristics of the animals were calculated using MedCalc and GraphPad Prism 8.0. Results Overall, similar levels of a lower sensitivity (67-68%) were seen for both the commercial EIE-LVC test and the Q5 ELISA when all assessed sera were considered, but a much greater sensitivity (92%) was seen for those from symptomatic dogs only. In contrast, a large number of negative results were observed for the DPP-positive sera from asymptomatic dogs or those with no clinical information available. A selection of those were tested yet again in new ELISA assays using a second batch of the Q5, purified under milder denaturing conditions, as well as another recombinant protein (Lci13). Conclusions The results reveal a higher-than-expected incidence of false-positive results for DPP, reinforcing the need for other recombinant proteins, such as the chimeric Q5, to be investigated as possible alternatives to the currently used CVL diagnostic methods.

1 January 2026 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
WSWagner José Tenório dos Santos
Wagner José Tenório dos Santos
NNNatalia Rocha Nadaes
Natalia Rocha Nadaes
ADAllana Kelly Oliveira Dutra
Allana Kelly Oliveira Dutra
ASAdalucia da Silva
Adalucia da Silva
HSHemilly Rayanne Ferreira da Silva
Hemilly Rayanne Ferreira da Silva
ONOsvaldo P. de Melo Neto
Osvaldo P. de Melo Neto
BACKGROUND Visceral leishmaniasis (VL), caused by Leishmania infantum, is the most severe form of leishmaniasis, prevalent in many countries, but still with limitations in diagnosis for both human and canine hosts. Serological assays based on recombinant proteins are the most efficient diagnostic alternatives, with the rapid diagnostic test (RDT) being the most cost-effective. The previously described chimeric Q5 is a recombinant protein derived from three native L. infantum antigens, which is potentially useful for both human and canine VL diagnosis, through preliminary enzyme-linked immunosorbent assay (ELISA), but which was not evaluated within an RDT setting. OBJECTIVES To evaluate the diagnostic performance of the chimeric recombinant protein Q5 in both ELISA and RDT formats for the detection of human and canine VL, and to compare its performance with RDTs based on Lci2 and Lci13 antigens. METHODS Here, we first expanded the Q5 evaluation through ELISA with a larger set of human and canine VL-positive sera from multiple origins. We confirmed a sensitivity ranging between 80% and 90% for the human VL and greater than 90% with the canine VL sera. A new RDT-Q5 was then set up and tested with multiple batches of human and canine sera. FINDINGS An improved performance was seen for the human VL diagnosis (94% sensitivity), but it was reduced with canine sera (86% sensitivity). Specificity values for both the ELISA-Q5 and RDT-Q5 were generally greater than 95%, with limited (8%) or no false-positive results with human sera from individuals with cutaneous leishmaniasis (CL) and Chagas disease (CD), respectively. The RDT-Q5 performance was compared with RDTs based on two other recombinant proteins, Lci2 and Lci13, tested respectively for the human and canine VL diagnosis. MAIN CONCLUSIONS Despite an equivalent performance for the human VL diagnosis, the RDT-Lci2 led to a much greater incidence of false-positive results with the CL and CD sera. In contrast, no setup for the RDT-Lci13 was effective with the canine sera. Our results confirm the RDT-Q5 as an efficient alternative for the VL diagnosis in the field, particularly for the human form of the disease.